You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Novel Magnetic Field Sensor
SBC: DYNAMIC STRUCTURES AND MATERIALS, LLC Topic: N/AN/A
SBIR Phase I 1999 Department of DefenseMissile Defense Agency -
A Novel Method for Fabricating Ultra Low-Cost Radial Gradient-Index Glass Rods for Optic Communication Networks
SBC: BEAMTEK, INC. Topic: N/AThis SBIR Phase II project proposed to develop a new fabrication technology that would lead to ultra low-cost, high quality radial gradient refractive index (GRIN) rods, which are widely used in fiber optic communications. Drastic cost reduction isexpected because several cost and labor intensive manufacturing processes will be eliminated, the product yield will be increased significantly compare ...
SBIR Phase II 2001 Department of DefenseMissile Defense Agency -
A Novel Radiometry‐Guided Ablation Catheter to Reliably Treat Barrett's Esophagus
SBC: Symple Surgical Inc Topic: 102ABSTRACT In the fight to eradicate esophageal cancer, Symple Surgical aims to develop a low-cost versatile ablation system for Barrettandapos;s esophagus (BE). BE is a serious complication of gastro-esophageal reflux disease (GERD) which affects ~40% of the US population. In more than 1.6% of people, chronic exposure to acid reflux induces BE, an esophageal epithelium abnormality that can develop ...
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS
SBC: ENDURX PHARMACEUTICALS INC Topic: 102DESCRIPTION provided by applicant Glioblastoma multiforme GBM or andquot glioblastoma andquot is the most common and aggressive malignant primary brain tumor in humans An effective treatment that increases patient survival would represent a significant advance in the field and provide a desperately needed new therapy for this deadly disease EnduRx is focused on the development of new tar ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Antiatherogenic Properties of tert-Butylhydroquinone
SBC: BIOINVENTIONS, LLC Topic: N/ADESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and tri ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Antiatherogenic Properties of tert-Butylhydroquinone
SBC: BIOINVENTIONS, LLC Topic: N/ADESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Antibody isotyping for discrimination of disease stage and diagnosis of early Lyme disease.
SBC: IMMUNO TECHNOLOGIES INC Topic: NIAIDABSTRACT More than 3 million tests are performed each year to support the laboratory diagnosis of human Lyme disease (LD). While the CDC conventional standard two-tier (CSTT) approach for serodiagnosis of LD has worked relatively well when used as recommended, there is plenty of room for improvement. Of a number of weaknesses associated with the supplemental immunoblot of the CSTT the most signifi ...
SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Anticancer redox inhibitor,Pleurotin
SBC: PROLX PHARMACEUTICALS CORPORATION Topic: N/ADESCRIPTION (provided by applicant): One in every four deaths in the US is due to cancer. The overall cancer drug market exceeds $2 billion in the USA. There is significant need to identify novel and selective small molecule-based cancer therapies. This proposal seeks to undertake preclinical evaluation of a novel clinical candidate that targets the thioredoxin reductase enzyme, for the eventu ...
SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
Antimicrobial-Coated Granular Filter Media for Drinking Water Treatment
SBC: Coating Systems Laboratories, Inc. Topic: TopicECoating Systems Laboratories, Inc., of Chandler, Arizona, has developed a quaternary ammonium chloride (QAC) coating with antimicrobial properties that may be attached to common granular filter media such as sand and zeolite. The potential for coating filter media to improve drinking water treatment with respect to both disinfection efficiency and the production of disinfection by-products could i ...
SBIR Phase I 2010 Environmental Protection Agency -
Antimicrobial Coated Granular Filter Media for Drinking Water Treatment
SBC: Coating Systems Laboratories, Inc. Topic: 09NCERE1Coating Systems Laboratories, Inc., of Chandler, Arizona, has developed a quaternary ammonium chloride (QAC) coating with antimicrobial properties that may be attached to common granular filter media such as sand and zeolite. The potential for coating filter media to improve drinking water treatment with respect to both disinfection efficiency and the production of disinfection by-products co ...
SBIR Phase I 2010 Environmental Protection Agency